Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer
Status:
Recruiting
Trial end date:
2022-02-05
Target enrollment:
Participant gender:
Summary
Nonrandomized, open label, single arm, Simon's two stage MinMax design trial of neoadjuvant
weekly carboplatin plus paclitaxel, followed by doxorubicin and cyclophosphamide in patients
with operable Triple Negative Breast Cancer (TNBC)